All In MedTech

FDA Clearance Tracker · P030047

CORDIS PRECISE NITINOL STENT SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Sep 22, 2006 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Sep 22, 2006

Approved

Time to decision

1,080 days

Received Oct 8, 2003. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P030047
Device name
CORDIS PRECISE NITINOL STENT SYSTEM
Applicant location
Miami Lakes, FL
Received
Oct 8, 2003
Decided
Sep 22, 2006
Decision
Approved
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
51 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NIM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE CORDIS PRECISE NITINOL STENT SYSTEM (5.5 FR AND 6.0 FR SIZES, OVER-THE-WIRE CONFIGURATION). THIS DEVICE IS INDICATED FOR USE IN CONJUNCTION WITH THE ANGIOGUARD XP EMBOLI CAPTURE GUIDEWIRE FOR THE TREATMENT OF PATIENTS AT HIGH RISK FOR ADVERSE EVENTS FROM CAROTID ENDARTERECTOMY (DEFINED IN THE IFU) WHO REQUIRE CAROTID REVASCULARIZATION AND MEET THE CRITERIA OUTLINED BELOW: 1) PATIENTS WITH NEUROLOGICAL SYMPTOMS AND >=50% STENOSIS OF THE COMMON OR INTERNAL CAROTID ARTERY BY ULTRASOUND OR ANGIOGRAM OR PATIENTS WITHOUT NEUROLOGICAL SYMPTOMS AND >=80% STENOSIS OF THE COMMON OR INTERNAL CAROTID ARTERY BY ULTRASOUND OR ANGIOGRAM, AND 2) PATIENTS MUST HAVE A VESSEL DIAMETER OF 4-9MM AT THE TARGET LESION. THE VESSEL DISTAL TO THE TARGET LESION MUST BE WITHIN THE RANGE OF 3MM AND 7.5MM TO ALLOW FOR PLACEMENT OF THE ANGIOGUARD XP EMBOLI CAPTURE GUIDEWIRE.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NIM. The earliest in FDA's data is P040012, decided Aug 30, 2004.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Cordis US Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.